Biotechnology company developing allogeneic T-cell immunotherapies for severe autoimmune diseases and cancers.
Atara Biotherapeutics, Inc. is a pioneering biotechnology company focused on developing innovative therapies for patients grappling with solid tumors, hematologic cancers, and autoimmune disorders across the United States. The company's flagship product, Tab-cel (tabelecleucel), represents a leading T-cell immunotherapy program currently advancing through Phase 3 clinical trials. Tab-cel targets Epstein-Barr virus (EBV)-driven post-transplant lymphoproliferative disease and nasopharyngeal carcinoma, showcasing its potential to address critical unmet medical needs.
In addition to Tab-cel, Atara Biotherapeutics is actively developing a robust pipeline of CAR T immunotherapy products. These include ATA2271 and ATA3271, designed to target mesothelin, and ATA3219, aimed at treating B-cell malignancies. The company is also advancing ATA188, currently in Phase 2 clinical trials for the treatment of multiple sclerosis, underscoring its commitment to leveraging innovative immunotherapy approaches across diverse therapeutic areas.
Atara Biotherapeutics has forged strategic alliances to bolster its research and development capabilities. Collaborations with renowned institutions like Memorial Sloan Kettering Cancer Center and QIMR Berghofer Medical Research Institute highlight its collaborative efforts to advance cutting-edge therapies. Additionally, a strategic collaboration with H. Lee Moffitt Cancer Center underscores Atara's commitment to expanding its portfolio and accelerating the development of novel treatment modalities.
Founded in 2012 and headquartered in Thousand Oaks, California, Atara Biotherapeutics continues to redefine possibilities in biotechnology. The company's steadfast dedication to scientific innovation and strategic partnerships positions it at the forefront of advancing transformative therapies for patients facing complex medical challenges.